We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Inari Medical, Inc. is a commercial-stage medical device company committed toward developing products to treat and change the lives of patients suffering from venous diseases. Its initial product offering comprises 2 minimally-invasive, novel catheter-based mechanical thrombectomy devices. It built its products purposely on the basis of the specific characteristics of the venous system and the treatment of the two distinct indications of venous thromboembolism or VTE (deep vein thrombosis and pulmonary embolism/ PE). Its FlowTriever product is the first thrombectomy system, which is FDA-cleared, used for the treatment of PE. Its advanced systems & processes to control the key relationships between its sales representatives and treating physicians like cardiologists, radiologists, helps it to quickly iterate products, launch and execute physician education and training programs and scale its sales organization. The company markets and sells its products to hospitals across the U.S.
- Recent NARI Stock Price: $41.60
- Yearly Gain for NARI stock: -34.82%
- Market Cap for NARI stock: $2.41B
- P/E Ratio for NARI stock: -1386.67
Will NARI's stock price go up? Is there an accurate NARI stock forecast available?
TipRanks.com reports that Inari Medical, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $59.00. The target pricing ranges from a high NARI forecast of $84 down to a low forecast of $47. Inari Medical, Inc. (NARI)’s last closing stock price was $41.60 which would put the average price target at 41.83% upside.
In addition, TradingView issued a rating for NARI stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on NARI stock.
Other analysts covering NARI include:
- Adam Maeder of Piper Sandler issued a Hold rating with the price target of $50 on 18 hours ago
- Larry Biegelsen of Wells Fargo issued a Buy rating with the price target of $84 on 18 hours ago
- William Plovanic of Canaccord Genuity issued a Buy rating with the price target of $55 on 18 hours ago
If you are wondering if NARI is a good stock to buy, here are 3rd party ratings for NARI stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Strong Sell, Bottom 43% (143 out of 251)
What is the sentiment on the street regarding Inari Medical, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for NARI stock: Bearish
- Blogger Consensus for NARI stock:
- Media Buzz for NARI stock: Sell
- Insider Signal for NARI stock: Balanced
- Investor Sentiment for NARI stock: Negative
- Hedge Fund signal for NARI stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on NARI stock including scouring the social networks like NARI StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for NARI stock chart >>
Summary: Merit Medical Systems, Inc. provides various peripheral and cardiac intervention products to cure cardiac conditions specific to interventional cardiology and electrophysiology. The company offers products focused in five core product groups: peripheral intervention, cardiac intervention, interventional oncology and spine, cardiovascular and critical care as well as endoscopy. However, the company operates in two revenue segments: Cardiovascular and Endoscopy Devices.
- Recent MMSI Stock Price: $76.63
- Yearly Gain for MMSI stock: -6.69%
- Market Cap for MMSI stock: $4.44B
- P/E Ratio for MMSI stock: 47.3
Will MMSI's stock price go up? Is there an accurate MMSI stock forecast available?
TipRanks.com reports that Merit Medical Systems, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $96.00. The target pricing ranges from a high MMSI forecast of $97 down to a low forecast of $100. Merit Medical Systems, Inc. (MMSI)’s last closing stock price was $76.63 which would put the average price target at 25.28% upside.
In addition, TradingView issued a rating for MMSI stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on MMSI stock.
Other analysts covering MMSI include:
- John Young CFA of Canaccord Genuity issued a Buy rating with the price target of $102 on 18 hours ago
- Jason Bednar of Piper Sandler issued a Buy rating with the price target of $97 on 18 hours ago
- Michael Matson of Needham issued a Buy rating with the price target of $85 on 18 hours ago
If you are wondering if MMSI is a good stock to buy, here are 3rd party ratings for MMSI stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Buy, Top 40% (100 out of 251)
What is the sentiment on the street regarding Merit Medical Systems, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for MMSI stock: Bearish
- Blogger Consensus for MMSI stock:
- Media Buzz for MMSI stock: Strong Buy
- Insider Signal for MMSI stock: Balanced
- Investor Sentiment for MMSI stock: Positive
- Hedge Fund signal for MMSI stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on MMSI stock including scouring the social networks like MMSI StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MMSI stock chart >>
Summary: CVRx Inc. is a commercial-stage medical device company. It focused on developing, manufacturing and commercializing neuromodulation solutions for patients with cardiovascular diseases. CVRx Inc. is headquartered in Minneapolis, MN.
- Recent CVRX Stock Price: $10.12
- Yearly Gain for CVRX stock: -20.63%
- Market Cap for CVRX stock: $218.55M
- P/E Ratio for CVRX stock: -5.09
Will CVRX's stock price go up? Is there an accurate CVRX stock forecast available?
TipRanks.com reports that CVRx, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $17.25. The target pricing ranges from a high CVRX forecast of $23 down to a low forecast of $13. CVRx, Inc. (CVRX)’s last closing stock price was $10.12 which would put the average price target at 70.45% upside.
In addition, TradingView issued a rating for CVRX stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on CVRX stock.
Other analysts covering CVRX include:
- Matthew O'Brien of Piper Sandler issued a Buy rating with the price target of $15 on 18 hours ago
- Chase Knickerbocker of Craig-Hallum issued a Buy rating with the price target of $23 on 18 hours ago
- Frank Takkinen of Lake Street issued a Buy rating with the price target of $18 on 18 hours ago
If you are wondering if CVRX is a good stock to buy, here are 3rd party ratings for CVRX stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 43% (143 out of 251)
What is the sentiment on the street regarding CVRx, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for CVRX stock: Bullish
- Blogger Consensus for CVRX stock:
- Media Buzz for CVRX stock: Sell
- Insider Signal for CVRX stock: Buying
- Investor Sentiment for CVRX stock: Negative
- Hedge Fund signal for CVRX stock: High Risk
The stock market is extremely volatile, and you need to do your own research on CVRX stock including scouring the social networks like CVRX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CVRX stock chart >>
Summary: Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.
- Recent INCY Stock Price: $52.94
- Yearly Gain for INCY stock: -29.73%
- Market Cap for INCY stock: $11.89B
- P/E Ratio for INCY stock: 16.04
Will INCY's stock price go up? Is there an accurate INCY stock forecast available?
TipRanks.com reports that Incyte Corporation currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $72.00. The target pricing ranges from a high INCY forecast of $84 down to a low forecast of $52. Incyte Corporation (INCY)’s last closing stock price was $52.94 which would put the average price target at 36.00% upside.
In addition, TradingView issued a rating for INCY stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has short-term outlook. Remember, securities are volatile, so please do your own research on INCY stock.
Other analysts covering INCY include:
- Jay Olson of Oppenheimer issued a Buy rating with the price target of $84 on 18 hours ago
- Evan Seigerman of BMO Capital issued a Hold rating with the price target of $52 on 18 hours ago
If you are wondering if INCY is a good stock to buy, here are 3rd party ratings for INCY stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 29% (73 out of 251)
What is the sentiment on the street regarding Incyte Corporation? (Current ratings compiled by TipRanks.com)
- News Sentiment for INCY stock: Bearish
- Blogger Consensus for INCY stock:
- Media Buzz for INCY stock: Buy
- Insider Signal for INCY stock: Balanced
- Investor Sentiment for INCY stock: Negative
- Hedge Fund signal for INCY stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on INCY stock including scouring the social networks like INCY StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for INCY stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================